Pharma Commercial Mock

← All views·CI feed·API docs

ASCO

Meeting Library

AACR Annual Meeting 2026 · San Diego, CA

Abstract LBA4000LBA2026-04-02 · 20:00 CT · E450
KEYNOTE-924: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
H. Rugo, H. Borghaei, T. Mok, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
Plenary SessionMelanoma📄🖼️
Abstract LBA4001LBA2026-04-05 · 19:00 CT · Hall B1
Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
S. Peters, M. Reck · Royal Marsden Hospital
Plenary SessionMelanoma📄🖼️

Abstract LBA4000LBA

KEYNOTE-924: Keytruda (pembrolizumab) adjuvant in metastatic melanoma

H. Rugo¹, H. Borghaei, T. Mok, S. Modi, P. Schmid

¹ UCSF Helen Diller Family Comprehensive Cancer Center (presenter)

Plenary Session: Melanoma[view all in session]

2026-04-02 · 20:00 CT · E450 · Sponsor: Merck

Background: Despite the availability of immune checkpoint inhibitors, optimal first-line therapy for metastatic melanoma remains an open question. Keytruda (undefined) is a anti-PD-1 mAb.

Methods: II-phase, randomized trial (KEYNOTE-924, NCT48003058). Patients with metastatic melanoma were randomized to Keytruda or investigator's choice chemotherapy. Primary endpoint: overall survival.

Results: OS 64.6 months (HR 0.7, 95% CI 0.56-0.84, p<0.001). PFS 12.9 months. ORR 56.4%.

Conclusions: Median OS 64.6 months. HR 0.7 (95% CI 0.56–0.84). Grade ≥3 AEs consistent with prior reports.

Clinical trial information: NCT48003058

Citation: J Clin Oncol 44, 2026 (suppl 17; abstr LBA4000). DOI: 10.1200/JCO.2026.44.17_suppl.LBA4000

▸ Author disclosures

H. Rugo: Consulting/advisory — Merck; Research funding (institution) — Merck.